CS-3150 + Eplerenone
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Sep 1, 2016 โ Jul 11, 2017
NCT ID
NCT02890173About CS-3150 + Eplerenone
CS-3150 + Eplerenone is a phase 3 stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02890173. Target conditions include Essential Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02890173 | Phase 3 | Completed |
Competing Products
20 competing products in Essential Hypertension